 | | Vol. 10.33 – 25 August, 2021 |
| |
|
|
|
Researchers investigated the combined influence of CSCs, circRNA, and immune checkpoint inhibitors in non-small cell lung cancerprogression and therapy resistance. They constructed lung CSCs.
[Cell Death & Disease] |
|  | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists showed that brain expressed X-linked gene 2(BEX2), which is essential for dormant CSCs in cholangiocarcinoma, was highly expressed in human hepatocellular carcinoma (HCC) lesions compared to the adjacent normal lesions, and that in 41 HCC cases the BEX2high expression group was correlated with a poor prognosis.
[Cancer Science] |
|
|
|
| The authors discovered that the expression of P2Y6 was decreased upon the activation of the NK cells. In the P2Y6-deficient mice, they found that the deficiency of P2Y6 promoted the development of the NK precursor cells into immature NK and mature NK cells.
[Journal of Immunology] |
|
|
|
| Homemade ethanol-based garlic extract was administered to MCF7 and MCF10DCIS breast tumor cell lines grown under moderate hypoxia. Cell cycle, epithelial-to-mesenchymal transition and cancer stem cell markers were evaluated.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Scientists evaluated the phenotype switching associated with drug resistance in breast cancer cell lines and cell lineage obtained from Brazilian patients and highlighted the role of the cancer stem cell marker CD24 in the dynamics of cell plasticity and the acquirement of drug resistance.
[Scientific Reports] |
|
|
|
| Investigators explored the role and underlying mechanism of miR-663a in the proliferation, migration, invasion, and CSC-like properties of glioma cells.
[Cell Cycle] |
|
|
|
| Scientists successfully established lung adenocarcinoma cell lines with gefitinib resistance. Long-term gefitinib induction could increase the level of oxidative stress in lung adenocarcinoma cells and reduce the antioxidant capacity, resulting in the high expression of HIF-1 and ALDH1 and leading to the enrichment of CSCs, and a decreased response to gefitinib.
[Translational Oncology] |
|
|
|
| Faciogenital dysplasia 5 (FGD5) was knocked down in gastric cancer cell lines through two independent siRNAs against FGD5 and it was identified that FGD5 knockdown suppressed the CSC—like traits of gastric cancer cells through analyzing the expression of CSC markers, ALDH1 activity and spheroid-formation ability.
[Environmental Toxicology] |
|
|
|
| Primary cell lines derived from four high-grade colon adenocarcinoma tissues were treated with renin-angiotensin system inhibitors to investigate their effect on cellular metabolism, tumorsphere formation and transcription of pluripotency genes.
[PLoS One] |
|  |
|
|
|
| Investigators describe the identification, biological characteristics, and single-cell genome-wide variation in circulating tumor cells and summarizes the application of single-cell sequencing technology to tumor typing, metastasis analysis, progression detection, and adjuvant therapy.
[Molecular Cancer] |
|
|
|
| The authors summarize different strategies that intensify the temozolomide effect such as MGMT inhibition, development of novel imidazotetrazine analog, and combination therapy; with an aim to incorporate a successful treatment and increased overall survival in glioblastoma patients.
[Biochimica et Biophysica Acta-Reviews On Cancer] |
|
|
|
|
| Samyang Biopharm USA, Inc. global biotech subsidiary of the Samyang Holdings Pharmaceuticals Corp. announced today that the company has entered into a three-year research collaboration with Dr. Hyun-Sung Lee, Assistant Professor of Surgery and Director of the Systems Onco-Immunology Laboratory at Baylor College of Medicine.
[Samyang Biopharm USA, Inc. (BusinessWire, Inc.)] |
|
|
|
| Bio-Path Holdings, Inc. announced that the US FDA has reviewed and cleared the Investigational New Drug application for BP1002, the company’s second drug candidate, for an initial Phase I/Ib clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.
[Bio-Path Holdings, Inc.] |
|
|
|
|
| November 22 – 23, 2021
Ghent, Belgium |
|
|
|
|
|
| | Indiana University – Indianapolis, Indiana, United States |
|
|
|
| | Indiana University – Indianapolis, Indiana, United States |
|
|
|
| | Dana-Farber Cancer Institute- Boston, Massachusetts, United States |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
